DarioHealth Corp. (NASDAQ: DRIO) creates innovative mobile and digital tools that empower and engage users to lead healthier lives. DarioHealth’s “Real time. Real data. Real people” approach and strategy is positioning the company as a major player in the mHealth industry; an industry currently worth $10B and expected to reach $31B by 2020. DarioHealth’s flagship product, the Dario™ Smart Diabetes Management Solution, is a platform for diabetes management that combines an all-in-one blood glucose meter, native smartphone app (iOS & Android), website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.
The Dario Smart Diabetes Management Solution was granted U.S. FDA marketing clearance in December 2015 and is set to launch in the current quarter in the U.S. – the largest market in the world for glucose monitoring. LabStyle has been granted patents and is pursuing additional applications – in multiple areas covering the specific processes related to blood glucose level measurement, as well as more general methods for rapid body fluids testing using mobile devices and cloud-based services. Dario™ is currently available in the UK, New Zealand, Netherlands, Australia, Israel, Canada, Belgium, and Italy. Dario received reimbursement coverage in the UK, Australia, Israel, Italy, and Canada. Sequential quarterly revenues are growing rapidly, reflecting strong market adoption.